Erste Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Erste Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.59M	Sell	133,225 -56,500	-30%	-$3.96M	0.07%	225
2026 Q1	$13.2M	Buy	189,725 +79,500	+72%	+$5.76M	0.12%	169
2025 Q4	$8.33M	Sell	110,225 -30,000	-21%	-$1.97M	0.07%	205
2025 Q3	$7.29M	Hold	140,225	–	–	0.07%	205
2025 Q2	$6.29M	Hold	140,225	–	–	0.05%	251
2025 Q1	$4.92M	Hold	140,225	–	–	0.06%	227
2024 Q4	$3.92M	Hold	140,225	–	–	0.05%	258
2024 Q3	$3.5M	Hold	140,225	–	–	0.04%	270
2024 Q2	$3.53M	Buy	140,225 +33,000	+31%	+$902K	0.05%	260
2024 Q1	$3.31M	Buy	107,225 +23,000	+27%	+$782K	0.05%	263
2023 Q4	$3.52M	Buy	84,225 +16,000	+23%	+$481K	0.05%	252
2023 Q3	$1.85M	Hold	68,225	–	–	0.03%	283
2023 Q2	$1.16M	Hold	68,225	–	–	0.02%	348
2023 Q1	$1.17M	Buy	68,225 +30,000	+78%	+$350K	0.02%	336
2022 Q4	$289K	Hold	38,225	–	–	0.01%	463
2022 Q3	$390K	Hold	38,225	–	–	0.01%	442
2022 Q2	$338K	Hold	38,225	–	–	0.01%	468
2022 Q1	$396K	Sell	38,225 -19,000	-33%	-$195K	0.01%	457
2021 Q4	$812K	Hold	57,225	–	–	0.01%	381
2021 Q3	$2.73M	Sell	57,225 -19,200	-25%	-$1.03M	0.05%	253
2021 Q2	$4.59M	Hold	76,425	–	–	0.09%	211
2021 Q1	$4.52M	Buy	76,425 +19,425	+34%	+$1.27M	0.11%	190
2020 Q4	$3.85M	Hold	57,000	–	–	0.11%	192
2020 Q3	$2.11M	Hold	57,000	–	–	0.07%	239
2020 Q2	$1.86M	Hold	57,000	–	–	0.07%	242
2020 Q1	$1.52M	Hold	57,000	–	–	0.09%	211
2019 Q4	$2.1M	Buy	57,000 +34,000	+148%	+$943K	0.09%	204
2019 Q3	$463K	Buy	+23,000	New	+$636K	0.02%	326

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Erste Asset Management's BBIO Position: Q2 2026 in Review

Erste Asset Management reduced its BridgeBio Pharma (BBIO) stake by 30% in Q2 2026, selling an estimated $3.96M and leaving 133,225 shares worth $9.59M. The position accounts for 0.07% of the portfolio, ranked #225.

Erste Asset Management first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $13.2M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Erste Asset Management held 133,225 shares of BridgeBio Pharma worth $9.59M as of Q2 2026.
Erste Asset Management sold 56,500 BridgeBio Pharma shares in Q2 2026, an estimated $3.96M.
BridgeBio Pharma made up 0.07% of Erste Asset Management's portfolio in Q2 2026, its #225 holding.
Erste Asset Management first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
Erste Asset Management's BridgeBio Pharma position peaked at $13.2M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.